Evidence map›Paper›PMID 35448194›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation.

Tianqing Yan, Xiaolu Ma, Haoyun Hu, Zhiyun Gong, Hui Zheng, Suhong Xie, Lin Guo, Renquan Lu

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tianqing YanDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Shanghai 200032, China.ORCID 0000-0003-3410-0395
Xiaolu MaDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Shanghai 200032, China.
Haoyun HuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Shanghai 200032, China.
Zhiyun GongDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Shanghai 200032, China.
Hui ZhengDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Shanghai 200032, China.
Suhong XieDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Shanghai 200032, China.
Lin GuoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Shanghai 200032, China.
Renquan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to establish a prognosis-prediction model based on serological indicators in patients with epithelial ovarian cancer (EOC). Patients initially diagnosed as ovarian cancer and surgically treated in Fudan University Shanghai Cancer Center from 2014 to 2018 were consecutively enrolled. Serological indicators preoperatively were collected. A risk model score (RMS) was constructed based on the levels of serological indicators determined by receiver operating characteristic curves. We correlated this RMS with EOC patients’ overall survival (OS). Finally, 635 patients were identified. Pearson’s χ2 results showed that RMS was significantly related to clinical parameters. Kaplan−Meier analysis demonstrated that an RMS less than 3 correlated with a longer OS (p < 0.0001). Specifically, significant differences were perceived in the survival curves of different subgroups. Multivariate Cox analysis revealed that age (p = 0.015), FIGO stage (p = 0.006), ascites (p = 0.015) and RMS (p = 0.005) were independent risk factors for OS. Moreover, RMS combined with age, FIGO and ascites could better evaluate for patients’ prognosis in DCA analyses. Our novel RMS-guided classification preoperatively identified the prognostic subgroups of patients with EOC and showed higher accuracy than the conventional method, meaning that it could be a useful and economical tool for tailored monitoring and/or therapy.

Indexed as

AscitesOvarian NeoplasmsCarcinoma, Ovarian EpithelialChinaFemaleHumansPrognosisepithelial ovarian cancerprognosis predictionrisk model scoreserological indicators

Identifiers

PMID35448194
PMCPMC9029686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.